This company has been marked as potentially delisted and may not be actively trading. LightWave Acquisition (LWAC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock LWAC vs. CALT, MBX, ETHZ, SBTX, AVTE, NLTX, BIOA, CYBN, VIRI, and WHWKShould you be buying LightWave Acquisition stock or one of its competitors? The main competitors of LightWave Acquisition include Calliditas Therapeutics AB (publ) (CALT), MBX Biosciences (MBX), Flag Ship Acquisition (ETHZ), Silverback Therapeutics (SBTX), Aerovate Therapeutics (AVTE), Neoleukin Therapeutics (NLTX), BioAge Labs (BIOA), Cybin (CYBN), Virios Therapeutics (VIRI), and Whitehawk Therapeutics (WHWK). LightWave Acquisition vs. Its Competitors Calliditas Therapeutics AB (publ) MBX Biosciences Flag Ship Acquisition Silverback Therapeutics Aerovate Therapeutics Neoleukin Therapeutics BioAge Labs Cybin Virios Therapeutics Whitehawk Therapeutics Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and LightWave Acquisition (NASDAQ:LWAC) are both small-cap pharmaceutical preparations industry companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership. Is CALT or LWAC more profitable? LightWave Acquisition has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. LightWave Acquisition's return on equity of 0.00% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Calliditas Therapeutics AB (publ)-30.18% -212.04% -27.96% LightWave Acquisition N/A N/A N/A Does the media favor CALT or LWAC? In the previous week, Calliditas Therapeutics AB (publ)'s average media sentiment score of 0.00 equaled LightWave Acquisition'saverage media sentiment score. Company Overall Sentiment Calliditas Therapeutics AB (publ) Neutral LightWave Acquisition Neutral Do institutionals & insiders believe in CALT or LWAC? 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has higher valuation & earnings, CALT or LWAC? LightWave Acquisition has lower revenue, but higher earnings than Calliditas Therapeutics AB (publ). CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62LightWave AcquisitionN/AN/AN/AN/AN/A SummaryCalliditas Therapeutics AB (publ) and LightWave Acquisition tied by winning 3 of the 6 factors compared between the two stocks. Get LightWave Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for LWAC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LWAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LWAC vs. The Competition Export to ExcelMetricLightWave AcquisitionPharmaceutical Preparations Industry SectorNASDAQ ExchangeMarket Cap$299.60M$805.10M$2.47B$10.65BDividend YieldN/A4.84%13.83%4.74%P/E RatioN/A1.2527.7726.85Price / SalesN/A29.478,560.20135.13Price / CashN/A17.6460.0361.77Price / BookN/A7.653.416.70Net IncomeN/A-$7.66M-$445.27M$276.44M LightWave Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LWACLightWave AcquisitionN/A$9.96flatN/AN/A$299.60MN/A0.00N/ACALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180MBXMBX BiosciencesN/A$16.69-0.4%$39.88+138.9%N/A$562.70MN/A-3.6836High Trading VolumeETHZFlag Ship AcquisitionN/A$2.53-1.9%N/AN/A$416.01MN/A-0.177Gap DownSBTXSilverback TherapeuticsN/A$10.31+0.3%N/A-27.6%$371.76MN/A-4.2683High Trading VolumeAVTEAerovate TherapeuticsN/A$8.86+6.4%N/A-87.4%$256.81MN/A-2.9620High Trading VolumeNLTXNeoleukin TherapeuticsN/A$22.34+6.5%N/A-51.4%$209.95MN/A-7.1890High Trading VolumeBIOABioAge Labs0.2746 of 5 stars$5.61-4.9%N/AN/A$201.12MN/A0.00N/ACYBNCybinN/A$6.08-2.1%$85.00+1,298.0%N/A$156.42MN/A-1.3950High Trading VolumeVIRIVirios TherapeuticsN/A$6.41-0.2%$5.00-22.0%+4,751.3%$123.44MN/A-23.745Gap DownWHWKWhitehawk TherapeuticsN/A$1.96+1.0%N/AN/A$92.37M$25.98M-32.6721Positive News Related Companies and Tools Related Companies CALT Competitors MBX Competitors ETHZ Competitors SBTX Competitors AVTE Competitors NLTX Competitors BIOA Competitors CYBN Competitors VIRI Competitors WHWK Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LWAC) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredU.S. Government Blocked NVIDIA’s Buyout… Here’s WhyThe U.S. government doesn't normally block billion-dollar tech deals. But when NVIDIA tried to acquire this...Behind the Markets | SponsoredGOLD ALERTGold has shattered records, soaring past $3,800 an ounce... But Stansberry Senior Partner Dr. David "Doc" E...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LightWave Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share LightWave Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
